摘要
目的探讨阿托伐他汀对冠状动脉瘤样扩张患者血清C-反应蛋白水平的影响及意义。方法 30例冠状动脉瘤样扩张患者随机分入阿托伐他汀组及对照组。检测两组患者治疗前后血浆C-反应蛋白水平并比较两组的总有效率。结果两组治疗前后C-反应蛋白水平差异有统计学意义(P<0.05),但阿托伐他汀组较对照组改善更显著(P<0.05)。阿托伐他汀组显效8例,有效5例,无效2例,总有效率86.7%;对照组显效5例,有效5例,无效5例,总有效率66.7%;组间比较差异有统计学意义(P<0.05)。结论阿托伐他汀可显著降低冠状动脉瘤样扩张患者血浆C-反应蛋白水平,改善冠状动脉瘤样扩张患者的预后。
Objective To investigate the effects and roles of atorvastatin on plasma level of C-reactive protein in patients with coronary artery ectasia. Methods We studied 30 patients with coronary artery ectasia patients were randomly assigned to atorvastatin group and control group. In the atorvastatin group, the patients re- ceived atorvastatin tablets 20 mg. The level of C-reactive protein before and after atorvastatin oral administration for 6 months were detected. The total effective rate were investigated between two group. Results The level of plasma C-reactive protein of both group were decreased markedly, a significant decreased of plasma C-reactive protein level were observed after taking atorvastatin for 6 months （ P 〈 0. 05 ）. In the atorvastatin group, there were effectual for 8, dffevtive for 5 and ineffective for 2, the total effective rate was 86. 7%. In the control group, there were effectual for 5, effective for 5 and ineffective for 5, the total effective rate was 66. 7%. A significant increased of the total effective rate were observed in the atorvastatin group compared with that of control group. Conclusion Atorvastatin could effectively decrease the level of plasma C-reactive protein and improve the prognosis of the patients with coronary artery ectasia.
出处
《中国实用医药》
2012年第5期17-18,共2页
China Practical Medicine
